NCT03608865: Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic brain metastasis or leptomeningeal seeding. If subjects are stable for 4 weeks without steroids after WBRT or GKS for symptomatic brain or leptomeningeal metastases, they will be eligible- see trial for details

Comments are closed.

Up ↑